ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 239,99
0,17%
Dow Jones
39 908,00
0,88%
DAX
18 869,36
0,78%
Brent Oil
82,855
0,24%
Bitcoin
65 975,74
-0,43%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Nkarta Inc (NKTX)

  7. Nkarta Inc (NKTX) Actualités

NKTX Nkarta Inc

6,88
0,33 (5,04%)
16 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Nkarta Inc NKTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,33 5,04% 6,88 00:00:10
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,76 6,60 7,21 6,88 6,55
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/5/202422:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:04EDGAR2Form 8-K - Current report
09/5/202422:01GLOBENkarta Reports First Quarter 2024 Financial Results and..
03/4/202422:02GLOBENkarta to Participate in Upcoming Investor Conferences
25/3/202411:30GLOBENkarta Announces Pricing of $240 Million Underwritten..
21/3/202421:01GLOBENkarta Reports Fourth Quarter and Full Year 2023 Financial..
05/3/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:32EDGAR2Form 144 - Report of proposed sale of securities
28/2/202414:01GLOBENkarta to Participate in Upcoming Investor Conferences
15/2/202403:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:20EDGAR2Form 144 - Report of proposed sale of securities
09/2/202412:38EDGAR2Form SC 13D/A - General statement of acquisition of..
18/1/202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202414:50EDGAR2Form 8-K - Current report
03/1/202422:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/12/202302:31GLOBENkarta Presents NKX101 Clinical Data at the 2023 American..
13/11/202314:25EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/11/202322:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:02GLOBENkarta Reports Third Quarter 2023 Financial Results and..
07/11/202314:02GLOBENkarta to Participate at Upcoming Investor Conferences
27/10/202322:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
17/10/202318:00DJNNkarta's Stock Climbs 28% After FDA Approves Drug..
17/10/202317:47PRNUSLupus Therapeutics Announces Partnership to Support the..
17/10/202313:06EDGAR2Form 8-K - Current report
17/10/202313:01GLOBENkarta Receives FDA Clearance of IND Application for NKX019..
16/10/202322:07EDGAR2Form 8-K - Current report
16/10/202322:01GLOBENkarta to Host Conference Call on Tuesday, October 17 at 8am..
23/8/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:05EDGAR2Form 8-K - Current report
10/8/202313:01GLOBENkarta Reports Second Quarter 2023 Financial Results and..
03/8/202314:02GLOBENkarta to Participate at Upcoming Investor Conference
05/7/202322:09EDGAR2Form 8-K - Current report
05/7/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202322:02GLOBENkarta Appoints Alyssa Levin Chief Financial and Business..
27/6/202313:01GLOBENkarta Updates Clinical Progress of CAR-NK Cell Therapy..
26/6/202322:01GLOBENkarta to Host Conference Call to Discuss Updated Clinical..
10/6/202316:47GLOBENkarta Presents NKX019 Clinical Data at the European..

Dernières Valeurs Consultées

NASDAQ
NKTX
Nkarta
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés